Premium
Genotropin 1 16 IU KabiVial is More Convenient than Conventional Administration Systems for Children on Growth Hormone Therapy
Author(s) -
DANIELSON K.,
NEUMEYER L.,
RITZÉN M.
Publication year - 1990
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.1990.tb11702.x
Subject(s) - medicine , growth hormone , administration (probate law) , hormone therapy , hormone , pediatrics , cancer , breast cancer , political science , law
. The use of a new device for reconstitution and storage of growth hormone (GH), Genotropin KabiVial, was studied in 20 children, aged 9‐17 years, who had been receiving GH therapy using conventional administration systems. After 2 weeks of treatment, the convenience of the device and the patients’tolerance of it were assessed by the patients/families through a questionnaire. They were asked to compare the new device with the conventional method (standard vials and syringes). Most of the patients found the new device superior to the conventional method; they found that it was easier to reconstitute the GH and considered the multi‐dose system and the smaller injection volume to be advantageous. Ninety per cent of the patients ( p < 0.001) expressed a preference for Genotropin 16 IU KabiVial for their future therapy.